Screener
Protagonist Therapeutics PTGX Net Income
Net Income at other companies
Other financials
Where this comes from
Reported directly by Protagonist Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:NetIncomeLoss.
The source filing: Protagonist Therapeutics’s 10-Q, filed August 5, 2026. Open the filing →
- Filed
- Aug 5, 2026, 4:17 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001104659-26-091123
FAQ
- What is Protagonist Therapeutics's net income?
- Protagonist Therapeutics (PTGX) reported net income of $162.85M in Q2 2026.
- How has Protagonist Therapeutics's net income changed year-over-year?
- Protagonist Therapeutics's net income increased by 568.3% year-over-year, from -$34.77M to $162.85M.
- What is the long-term trend for Protagonist Therapeutics's net income?
- Over 3 years (2021 to 2025), Protagonist Therapeutics's net income has grown at a 1.2% compound annual growth rate (CAGR), from -$125.55M to -$130.15M.
- What does net income mean?
- The bottom line — total revenue minus all expenses, taxes, and costs. Represents the profit attributable to the company's shareholders after all obligations are met.
Ask your AI about Protagonist Therapeutics's net income.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude